Sign In
Buy RANI
$0.774
-0.0462 (-5.63%)
At Close: Jul 31, 2026
Rani Therapeutics to Participate in May Investor Conferences
08:00am, Tuesday, 14'th May 2024
SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral
SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral
Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update
04:05pm, Monday, 06'th May 2024
- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Initiation of Phase 2 clinical trial for RT-102 for the treatment of osteoporosis expect
Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript
07:05pm, Wednesday, 20'th Mar 2024
Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript
Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update
04:05pm, Wednesday, 20'th Mar 2024
- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Announced Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Tr
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
04:05pm, Friday, 15'th Mar 2024
SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the or
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Rani Therapeutics Holdings, Inc. (NASDAQ: RANI)
08:30am, Tuesday, 09'th Jan 2024
NEW YORK , Jan. 9, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) on behalf of the company's shareholders. The invest
Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist
08:00am, Thursday, 14'th Dec 2023
- Transenteric delivery of incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study –
What Makes Rani Therapeutics Holdings, Inc. (RANI) a New Buy Stock
01:32pm, Thursday, 07'th Dec 2023
Rani Therapeutics Holdings, Inc. (RANI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update
04:05pm, Wednesday, 08'th Nov 2023
- Cash runway extended into 2025 - - Announced strategic program prioritization, expansion of manufacturing and plans to streamline business operations - - Initiated Phase 1 clinical trial of RT-111,
Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study
04:05pm, Thursday, 19'th Oct 2023
- RaniPill ® HC achieved 4/4 successful drug delivery of orally administered Humira® (adalimumab) -
Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research
04:05pm, Thursday, 12'th Oct 2023
SAN JOSE, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the ora
Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)
08:00am, Monday, 18'th Sep 2023
- Topline results from this study are expected in early Q1 2024 - Celltrion has a right of first negotiation for RT-111 following positive Phase 1 results SAN JOSE, Calif., Sept. 18, 2023 (GLOBE NEWSW
Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies
04:05pm, Thursday, 07'th Sep 2023
- Two preclinical studies of RaniPill® HC achieved 18/20 successful drug delivery of orally administered teriparatide resulting in a cumulative 90% success rate
Rani Therapeutics to Participate in September Investor Conferences
08:00am, Wednesday, 06'th Sep 2023
SAN JOSE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the or
